China
Africa
Explore chapters and articles related to this topic
Antituberculosis induced drug reaction with eosinophilia and systemic symptoms in a pediatric latent tuberculosis infection overdiagnosed as tuberculosis disease
Published in Ade Gafar Abdullah, Isma Widiaty, Cep Ubad Abdullah, Medical Technology and Environmental Health, 2020
W. Setiowulan, R. Rulandani, H.S. Rachman
The most important treatment of DRESS syndrome is immediate removal of the offending drug. In some cases, this may be sufficient to achieve the resolution of clinical and laboratory abnormalities (Allouchery et al. 2017, Choudhary et al. 2013). The pharmacological approach to treating this syndrome is not completely defined as such treatments have not yet been evaluated in clinical trials. Intravenous corticosteroids, administered alone or followed by oral steroid therapy, have been shown to be an effective treatment for DRESS syndrome. However, there is no consensus regarding the dose and route of administration (Oberlin et al. 2019).
Systemic complications of osteoporosis medical treatment
Published in Peter V. Giannoudis, Thomas A. Einhorn, Surgical and Medical Treatment of Osteoporosis, 2020
Konstantinos G. Makridis, Stamatina-Emmanouela Zourntou
DRESS syndrome is a severe adverse drug-induced reaction presenting as a diffuse maculopapular skin rash with fever, hematologic abnormalities (leukocytosis, eosinophilia, and/or atypical lymphocytosis), and multiorgan involvement. In such cases, even more severe reactions may occur like systemic reactivation of human herpesviruses (HHV-6 and HHV-7), Epstein-Barr virus, and cytomegalovirus (31).
Drug-induced eosinophilia and systemic symptoms
Published in Biju Vasudevan, Rajesh Verma, Dermatological Emergencies, 2019
Rajesh Verma, Pradeesh Arumugam
DRESS syndrome is a severe adverse drug reaction that may be fatal in 10% of patients [60]. Poor prognostic factors include eosinophilia, pancytopenia, leukocytosis, thrombocytopenia, a history of chronic renal insufficiency, multiorgan involvement, tachycardia, tachypnea, coagulopathy, gastrointestinal bleeding, systemic inflammatory response syndrome, and raised creatinine and ferritin levels at initial presentation [61].
Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review
Published in Expert Review of Clinical Pharmacology, 2020
Renato de Filippis, Pau Soldevila-Matías, Pasquale De Fazio, Daniel Guinart, Inmaculada Fuentes-Durá, Jose M. Rubio, John M. Kane, Georgios Schoretsanitis
The clinical features of DRESS invariably include cutaneous eruption, fever, hematologic abnormalities with eosinophilia and/or atypical lymphocytosis, involvement of at least one internal organ and/or generalized lymphadenopathy [10,11]. The multi-visceral involvement differentiates DRESS from other cutaneous drug reactions [12,13]. The debate regarding the diagnosis of DRESS syndrome has evolved in recent years and various diagnostic criteria have been suggested [14]. There are two major assessment tools for DRESS: the first was developed by a multinational registry study group investigating severe cutaneous adverse reactions (RegiSCAR), the RegiSCAR criteria [15]. The second diagnostic tool was developed by a Japanese group and contains similar criteria with RegiSCAR, but also considers the role of the reactivation of human herpesvirus 6 (HHV-6) [16].
Drug reaction with eosinophilia and systemic symptoms in a child with N-methyl-d -aspartate receptor encephalitis
Published in Baylor University Medical Center Proceedings, 2019
Kristen Taylor, Rajashree Srinivasan
Patients in inpatient rehabilitation frequently arrive with new diagnoses, requiring a vast array of new medications. Clinicians are responsible for monitoring effectiveness and potential adverse reactions, many of which can be vague and involve minimal risk. This is not the case with DRESS syndrome, with an ∼10% mortality rate and potentially months-long recovery process. Patients with a history of DRESS are at risk of future flares and can experience symptoms within other classes of medications, such as antibiotics or antipsychotics.8 DRESS syndrome can be caused by many medications that are frequently used within the inpatient rehabilitation patient population and should be on the differential diagnosis list of any patient with new symptoms of rash, swelling, and abnormal laboratory findings.
The case of the magenta woman (DRESS syndrome)
Published in Baylor University Medical Center Proceedings, 2020
DRESS syndrome is a rare, potentially life-threatening drug-induced hypersensitivity reaction. The clinical manifestations of DRESS are not immediate and usually appear 2 to 8 weeks after introduction of the triggering drug. Common features consist of widespread skin rash, fever, hematological abnormalities, lymphadenopathy, and organ injury. Antiepileptics, sulfonamides, and allopurinol are the most common triggers; however, vancomycin has also been reported. Increased long-term requirements for vancomycin treatment for patients with osteomyelitis and endocarditis necessitate close monitoring for hypersensitivity reactions. Vancomycin-triggered DRESS has been increasingly reported over the past 5 years, with 26 cases reported to date.1